\documentclass[11pt,twoside]{article}\makeatletter \IfFileExists{xcolor.sty}% {\RequirePackage{xcolor}}% {\RequirePackage{color}} \usepackage{colortbl} \usepackage{wrapfig} \usepackage{ifxetex} \ifxetex \usepackage{fontspec} \usepackage{xunicode} \catcode`⃥=\active \def⃥{\textbackslash} \catcode`❴=\active \def❴{\{} \catcode`❵=\active \def❵{\}} \def\textJapanese{\fontspec{Noto Sans CJK JP}} \def\textChinese{\fontspec{Noto Sans CJK SC}} \def\textKorean{\fontspec{Noto Sans CJK KR}} \setmonofont{DejaVu Sans Mono} \else \IfFileExists{utf8x.def}% {\usepackage[utf8x]{inputenc} \PrerenderUnicode{–} }% {\usepackage[utf8]{inputenc}} \usepackage[english]{babel} \usepackage[T1]{fontenc} \usepackage{float} \usepackage[]{ucs} \uc@dclc{8421}{default}{\textbackslash } \uc@dclc{10100}{default}{\{} \uc@dclc{10101}{default}{\}} \uc@dclc{8491}{default}{\AA{}} \uc@dclc{8239}{default}{\,} \uc@dclc{20154}{default}{ } \uc@dclc{10148}{default}{>} \def\textschwa{\rotatebox{-90}{e}} \def\textJapanese{} \def\textChinese{} \IfFileExists{tipa.sty}{\usepackage{tipa}}{} \fi \def\exampleFont{\ttfamily\small} \DeclareTextSymbol{\textpi}{OML}{25} \usepackage{relsize} \RequirePackage{array} \def\@testpach{\@chclass \ifnum \@lastchclass=6 \@ne \@chnum \@ne \else \ifnum \@lastchclass=7 5 \else \ifnum \@lastchclass=8 \tw@ \else \ifnum \@lastchclass=9 \thr@@ \else \z@ \ifnum \@lastchclass = 10 \else \edef\@nextchar{\expandafter\string\@nextchar}% \@chnum \if \@nextchar c\z@ \else \if \@nextchar l\@ne \else \if \@nextchar r\tw@ \else \z@ \@chclass \if\@nextchar |\@ne \else \if \@nextchar !6 \else \if \@nextchar @7 \else \if \@nextchar (8 \else \if \@nextchar )9 \else 10 \@chnum \if \@nextchar m\thr@@\else \if \@nextchar p4 \else \if \@nextchar b5 \else \z@ \@chclass \z@ \@preamerr \z@ \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi \fi} \gdef\arraybackslash{\let\\=\@arraycr} \def\@textsubscript#1{{\m@th\ensuremath{_{\mbox{\fontsize\sf@size\z@#1}}}}} \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \def\abbr{} \def\corr{} \def\expan{} \def\gap{} \def\orig{} \def\reg{} \def\ref{} \def\sic{} \def\persName{}\def\name{} \def\placeName{} \def\orgName{} \def\textcal#1{{\fontspec{Lucida Calligraphy}#1}} \def\textgothic#1{{\fontspec{Lucida Blackletter}#1}} \def\textlarge#1{{\large #1}} \def\textoverbar#1{\ensuremath{\overline{#1}}} \def\textquoted#1{‘#1’} \def\textsmall#1{{\small #1}} \def\textsubscript#1{\@textsubscript{\selectfont#1}} \def\textxi{\ensuremath{\xi}} \def\titlem{\itshape} \newenvironment{biblfree}{}{\ifvmode\par\fi } \newenvironment{bibl}{}{} \newenvironment{byline}{\vskip6pt\itshape\fontsize{16pt}{18pt}\selectfont}{\par } \newenvironment{citbibl}{}{\ifvmode\par\fi } \newenvironment{docAuthor}{\ifvmode\vskip4pt\fontsize{16pt}{18pt}\selectfont\fi\itshape}{\ifvmode\par\fi } \newenvironment{docDate}{}{\ifvmode\par\fi } \newenvironment{docImprint}{\vskip 6pt}{\ifvmode\par\fi } \newenvironment{docTitle}{\vskip6pt\bfseries\fontsize{22pt}{25pt}\selectfont}{\par } \newenvironment{msHead}{\vskip 6pt}{\par} \newenvironment{msItem}{\vskip 6pt}{\par} \newenvironment{rubric}{}{} \newenvironment{titlePart}{}{\par } \newcolumntype{L}[1]{){\raggedright\arraybackslash}p{#1}} \newcolumntype{C}[1]{){\centering\arraybackslash}p{#1}} \newcolumntype{R}[1]{){\raggedleft\arraybackslash}p{#1}} \newcolumntype{P}[1]{){\arraybackslash}p{#1}} \newcolumntype{B}[1]{){\arraybackslash}b{#1}} \newcolumntype{M}[1]{){\arraybackslash}m{#1}} \definecolor{label}{gray}{0.75} \def\unusedattribute#1{\sout{\textcolor{label}{#1}}} \DeclareRobustCommand*{\xref}{\hyper@normalise\xref@} \def\xref@#1#2{\hyper@linkurl{#2}{#1}} \begingroup \catcode`\_=\active \gdef_#1{\ensuremath{\sb{\mathrm{#1}}}} \endgroup \mathcode`\_=\string"8000 \catcode`\_=12\relax \usepackage[a4paper,twoside,lmargin=1in,rmargin=1in,tmargin=1in,bmargin=1in,marginparwidth=0.75in]{geometry} \usepackage{framed} \definecolor{shadecolor}{gray}{0.95} \usepackage{longtable} \usepackage[normalem]{ulem} \usepackage{fancyvrb} \usepackage{fancyhdr} \usepackage{graphicx} \usepackage{marginnote} \renewcommand{\@cite}[1]{#1} \renewcommand*{\marginfont}{\itshape\footnotesize} \def\Gin@extensions{.pdf,.png,.jpg,.mps,.tif} \pagestyle{fancy} \usepackage[pdftitle={Rectal Adenocarcinoma with Synchronous Brain Metastasis and Prolonged Overall Survival (OS)}, pdfauthor={}]{hyperref} \hyperbaseurl{} \paperwidth210mm \paperheight297mm \def\@pnumwidth{1.55em} \def\@tocrmarg {2.55em} \def\@dotsep{4.5} \setcounter{tocdepth}{3} \clubpenalty=8000 \emergencystretch 3em \hbadness=4000 \hyphenpenalty=400 \pretolerance=750 \tolerance=2000 \vbadness=4000 \widowpenalty=10000 \renewcommand\section{\@startsection {section}{1}{\z@}% {-1.75ex \@plus -0.5ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large\bfseries}} \renewcommand\subsection{\@startsection{subsection}{2}{\z@}% {-1.75ex\@plus -0.5ex \@minus- .2ex}% {0.5ex \@plus .2ex}% {\reset@font\Large}} \renewcommand\subsubsection{\@startsection{subsubsection}{3}{\z@}% {-1.5ex\@plus -0.35ex \@minus -.2ex}% {0.5ex \@plus .2ex}% {\reset@font\large}} \renewcommand\paragraph{\@startsection{paragraph}{4}{\z@}% {-1ex \@plus-0.35ex \@minus -0.2ex}% {0.5ex \@plus .2ex}% {\reset@font\normalsize}} \renewcommand\subparagraph{\@startsection{subparagraph}{5}{\parindent}% {1.5ex \@plus1ex \@minus .2ex}% {-1em}% {\reset@font\normalsize\bfseries}} \def\l@section#1#2{\addpenalty{\@secpenalty} \addvspace{1.0em plus 1pt} \@tempdima 1.5em \begingroup \parindent \z@ \rightskip \@pnumwidth \parfillskip -\@pnumwidth \bfseries \leavevmode #1\hfil \hbox to\@pnumwidth{\hss #2}\par \endgroup} \def\l@subsection{\@dottedtocline{2}{1.5em}{2.3em}} \def\l@subsubsection{\@dottedtocline{3}{3.8em}{3.2em}} \def\l@paragraph{\@dottedtocline{4}{7.0em}{4.1em}} \def\l@subparagraph{\@dottedtocline{5}{10em}{5em}} \@ifundefined{c@section}{\newcounter{section}}{} \@ifundefined{c@chapter}{\newcounter{chapter}}{} \newif\if@mainmatter \@mainmattertrue \def\chaptername{Chapter} \def\frontmatter{% \pagenumbering{roman} \def\thechapter{\@roman\c@chapter} \def\theHchapter{\roman{chapter}} \def\thesection{\@roman\c@section} \def\theHsection{\roman{section}} \def\@chapapp{}% } \def\mainmatter{% \cleardoublepage \def\thechapter{\@arabic\c@chapter} \setcounter{chapter}{0} \setcounter{section}{0} \pagenumbering{arabic} \setcounter{secnumdepth}{6} \def\@chapapp{\chaptername}% \def\theHchapter{\arabic{chapter}} \def\thesection{\@arabic\c@section} \def\theHsection{\arabic{section}} } \def\backmatter{% \cleardoublepage \setcounter{chapter}{0} \setcounter{section}{0} \setcounter{secnumdepth}{2} \def\@chapapp{\appendixname}% \def\thechapter{\@Alph\c@chapter} \def\theHchapter{\Alph{chapter}} \appendix } \newenvironment{bibitemlist}[1]{% \list{\@biblabel{\@arabic\c@enumiv}}% {\settowidth\labelwidth{\@biblabel{#1}}% \leftmargin\labelwidth \advance\leftmargin\labelsep \@openbib@code \usecounter{enumiv}% \let\p@enumiv\@empty \renewcommand\theenumiv{\@arabic\c@enumiv}% }% \sloppy \clubpenalty4000 \@clubpenalty \clubpenalty \widowpenalty4000% \sfcode`\.\@m}% {\def\@noitemerr {\@latex@warning{Empty `bibitemlist' environment}}% \endlist} \def\tableofcontents{\section*{\contentsname}\@starttoc{toc}} \parskip0pt \parindent1em \def\Panel#1#2#3#4{\multicolumn{#3}{){\columncolor{#2}}#4}{#1}} \newenvironment{reflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemsep}{0pt}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\itshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{sansreflist}{% \begin{raggedright}\begin{list}{} {% \setlength{\topsep}{0pt}% \setlength{\rightmargin}{0.25in}% \setlength{\itemindent}{0pt}% \setlength{\parskip}{0pt}% \setlength{\itemsep}{0pt}% \setlength{\parsep}{2pt}% \def\makelabel##1{\upshape ##1}}% } {\end{list}\end{raggedright}} \newenvironment{specHead}[2]% {\vspace{20pt}\hrule\vspace{10pt}% \phantomsection\label{#1}\markright{#2}% \pdfbookmark[2]{#2}{#1}% \hspace{-0.75in}{\bfseries\fontsize{16pt}{18pt}\selectfont#2}% }{} \def\TheFullDate{2017-01-15 (revised: 15 January 2017)} \def\TheID{\makeatother } \def\TheDate{2017-01-15} \title{Rectal Adenocarcinoma with Synchronous Brain Metastasis and Prolonged Overall Survival (OS)} \author{}\makeatletter \makeatletter \newcommand*{\cleartoleftpage}{% \clearpage \if@twoside \ifodd\c@page \hbox{}\newpage \if@twocolumn \hbox{}\newpage \fi \fi \fi } \makeatother \makeatletter \thispagestyle{empty} \markright{\@title}\markboth{\@title}{\@author} \renewcommand\small{\@setfontsize\small{9pt}{11pt}\abovedisplayskip 8.5\p@ plus3\p@ minus4\p@ \belowdisplayskip \abovedisplayskip \abovedisplayshortskip \z@ plus2\p@ \belowdisplayshortskip 4\p@ plus2\p@ minus2\p@ \def\@listi{\leftmargin\leftmargini \topsep 2\p@ plus1\p@ minus1\p@ \parsep 2\p@ plus\p@ minus\p@ \itemsep 1pt} } \makeatother \fvset{frame=single,numberblanklines=false,xleftmargin=5mm,xrightmargin=5mm} \fancyhf{} \setlength{\headheight}{14pt} \fancyhead[LE]{\bfseries\leftmark} \fancyhead[RO]{\bfseries\rightmark} \fancyfoot[RO]{} \fancyfoot[CO]{\thepage} \fancyfoot[LO]{\TheID} \fancyfoot[LE]{} \fancyfoot[CE]{\thepage} \fancyfoot[RE]{\TheID} \hypersetup{citebordercolor=0.75 0.75 0.75,linkbordercolor=0.75 0.75 0.75,urlbordercolor=0.75 0.75 0.75,bookmarksnumbered=true} \fancypagestyle{plain}{\fancyhead{}\renewcommand{\headrulewidth}{0pt}} \date{} \usepackage{authblk} \providecommand{\keywords}[1] { \footnotesize \textbf{\textit{Index terms---}} #1 } \usepackage{graphicx,xcolor} \definecolor{GJBlue}{HTML}{273B81} \definecolor{GJLightBlue}{HTML}{0A9DD9} \definecolor{GJMediumGrey}{HTML}{6D6E70} \definecolor{GJLightGrey}{HTML}{929497} \renewenvironment{abstract}{% \setlength{\parindent}{0pt}\raggedright \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt \textcolor{GJBlue}{\large\bfseries\abstractname\space} }{% \vskip8pt \textcolor{GJMediumGrey}{\rule{\textwidth}{2pt}} \vskip16pt } \usepackage[absolute,overlay]{textpos} \makeatother \usepackage{lineno} \linenumbers \begin{document} \author[1]{B Losada Vila} \affil[1]{ Complutense Madrid} \renewcommand\Authands{ and } \date{\small \em Received: 15 December 2016 Accepted: 31 December 2016 Published: 15 January 2017} \maketitle \begin{abstract} A 61 years old woman with dizziness and gait disturbance in relation to brain metastases of a rectal adenocarcinoma (cT3N1M1). CT showed an unique frontal lesion and no further disease in other organs. Performance Status 1, so Digestive Tumors Committee decides surgical treatment of frontal brain metastasis and the histologic postsurgical examination showed microscopic affected margins.Then, radiation therapy (RT) of brain with radiosurgery and short course 5x5 of the primary tumor with low anterior resection was completed. After 2 months of brain RT, liver progression was discovered and then we decided neoadjuvant chemotherapy mFOLFOX6 and bevacizumab x 5 cycles with stable liver metastases and no other lesions. Following, limited liver resection and adjuvant chemotherapy was performed with the same schedule.No signs of tumor recurrence and more than 13 and 24 months of disease-free survival (DFS) and overall survival (OS) respectively was achieved in a metastasic cancer (brain metastasis) with usually OS 3 months. \end{abstract} \keywords{brain metastases, rectal adenocarcinoma, radiosurgery.} \begin{textblock*}{18cm}(1cm,1cm) % {block width} (coords) \textcolor{GJBlue}{\LARGE Global Journals \LaTeX\ JournalKaleidoscope\texttrademark} \end{textblock*} \begin{textblock*}{18cm}(1.4cm,1.5cm) % {block width} (coords) \textcolor{GJBlue}{\footnotesize \\ Artificial Intelligence formulated this projection for compatibility purposes from the original article published at Global Journals. However, this technology is currently in beta. \emph{Therefore, kindly ignore odd layouts, missed formulae, text, tables, or figures.}} \end{textblock*} \let\tabcellsep& \section[{I. Introduction}]{I. Introduction}\par olorectal cancer is the second leading cause of death in Spain and up to 20\% is diagnosed in an advanced stage, normally with hepatic or lung metastasis. Brain metastases are an uncommon complication of colorectal cancer (1.8-5\% of all BM), even more unusual in the beginning (<1\%). Overall survival(OS) after diagnosis of BM is 2.6 to 7.4 months. However, we try to perform metastesectomies whenever possible.\par We submit a rare case whith unique frontal brain metastases of rectal adenocarcinoma without affecting other organs. Emphasize on a multidisciplinary approach to achieve a prolonged survival. \section[{II. Case Presentation}]{II. Case Presentation}\par A 61 year-old woman, with no personal previous history who debut with dizziness, gait disturbance and memory loss. Performance Status 1. Occasional bleeding tools. No fever.\par First of all, brain CT showed a single lesion in left frontal lobe, so she was admitted to complete the study. To better qualify the lesion, brain MRI showed the same nodule, suggesting a metastasic disease (figure {\ref 1}). As digestive disorders were recent too, colonoscopy was the third test: mass occupying lesión 100\% of the circumference and medium rectum location. PA: lowgrade colorectal adenocarcinoma. (figure {\ref 2})\par CT chest-abdom-pelvis: no further disease. Pelvis MRI: 7cm tumor from anal margin. \section[{Clinical statage: cT3N1M1 (single brain metastasis).}]{Clinical statage: cT3N1M1 (single brain metastasis).}\par According to give a treatment with a curative intention, Tumor Committee decided brain surgery followed by short course rectal RT and low anterior resection (LAR). \section[{III. Differential Diagnosis}]{III. Differential Diagnosis}\par Approaching to a brain lesion discovered with no previous recent trauma, bleeding or halo images suggesting infection or abscess; first possibilities are malignancies and the most frequent ones are lymphoma, metastasis and astrocytoma / glioblastoma multiforme. Less common are ependymoma, tumors of the pineal gland or choroid plexus.\par In primary malignancies with brain metastases such as melanoma, lung, kidney or thyroid, brain lesions bleeding would be usual and MRI should be hyperintense on T2 lesion if bleeding was within 6 hours or hypointense on T2 if bleeding was after 24 hours.\par Central view for MRI is hyperintense with abscess, while in the tumor is hypointense.\par Definitive diagnosis is based on histology, and when the lesion is technically resectable, surgery resection must be performed with intraoperative confirmation. \section[{IV. Treatment}]{IV. Treatment} \section[{Digestive}]{Digestive}\par Tumor Committee decided neurosurgery because it was an unique and resectable lesion (10.09.2013). Performance Status 1.\par Definitive Histological diagnosis was a 3.1 x 2.2 x 2 cm metastasis of colorectal adenocarcinoma (CK20 +, CK7 -and CEA +) with extensive tumor necrosis. Microscopical surgical margin affected. Adjuvant treatment was mFOLFOX6 + Bevacizumab x 3 cycles and final toxicity was diarrhea and neuropathy. CT showed no signs of tumor recurrence at the end of treatment on 24/09/14. Actually Performance Status 0 and no neurologic symptoms. \section[{Volume XVII Issue 1 Version I}]{Volume XVII Issue 1 Version I} \section[{Outcome and Follow-Up}]{Outcome and Follow-Up}\par More than 26 months of DFS and more than 36 months of OS. \section[{V. Discussion}]{V. Discussion}\par Initial presentation as cerebral involvement is unusual, being 1-4\% the incidence of brain metastases associated to colorectal cancer. According to {\ref Ko Chu} Fang, 3773 patients with colorectal cancer were reviewed, which 37 (1.03\%) developed metastases between 1970 and 1996. 55\% had a solitary lesion while 45\% were multiple. Regarding location, 62\% were in temporoparietal lobes, 13\% in cerebellum, 13\% cerebellum and cerebrum, 8\% frontal lobe and 4\% in posterior fossa brain. Rectal origin occurs in 56.4\%. \hyperref[b0]{[1]} This case is unusual in rectal cancer disease because of the synchronous diagnosis and absence of metastatic disease in other organs (liver and lung as usual). In Kye series, 39 patients presented with colorectal brain metastases, 79.5\% presented with pulmonary metastases and only 1\% as an exclusive involvement in brain. \hyperref[b1]{[2]} In E Magni serie of 41 patients, 4.9\% did not involve other extracranial metastatic locations \hyperref[b2]{[3]} Diagnosis of brain metastases appear after a mean of 36 +/-19 months and diagnosis of colorectal cancer in 77\% of reported cases, with just a remaining 23\% present in the beginning. In E Magni serie, 17.1\% was synchronous too.\par According to the treatment, a literature review only describes very few cases treated with radiosurgery, being this indication increasing in those patients with multiple lesions <35 mm, minimum mass effect and affected margins.\par Results in NCCTG N0574 (Alliance) demonstrated better OS and quality of life with radiosurgery + RT \hyperref[b3]{[4]}. Recently, a literature review of 80 patients with brain metastasis reported OS of 6 months in patients who recevied gamma knife radiosurgery (22 patients), 3 months in whole radiotherapy and 13 months in 10 patients on gamma knife + whole radiotherapy. \hyperref[b4]{[5]} Among a serie of 41 patients (E Magni) OS after diagnosis of brain metastases was 5 months: 4.2 months in patients treated with radiotherapy (29.3\%), 11. 9 months in those with radio and chemotherapy (21.9 \%),and 21.4 months in those with surgery +/-radio or chemotherapy ( 29.3\%).\par We emphassyze our case with OS 24 months, never published.\par Also, prognostic factors in colorectal cancer has been studied to determine the best therapeutic approach. KRAS mutated patients use to present more common pulmonary and CNS involvement (62 and 56.5\%), and liver metastasis are less common. \hyperref[b5]{[6]}.\par Regarding primary tumor treatment, Shin et al published the results of RT short course schedule (5 days x 5 Gy) and it seems to be effective in local control and "down-staging" with 85\% R0 resections. \hyperref[b6]{[7,}\hyperref[b7]{8]} However, when hepatic progression is demonstrated, chemo is the preferred treatment. Adam showed a survival benefit after surgery in liver tumors in response, however this benefit was lower in progression disease. In the case, we decided initially neoadjuvant CT (ESMO Guidelines) with Bevacizumab (KRAS mutated) (Cairo-2, ARTIST): 45-55\% RR, PFS 9-12 months. \hyperref[b8]{[9,}\hyperref[b9]{10,}\hyperref[b10]{11]}. As a partial response was achieved after chemo and liver resection was feasible too, liver surgery was performed because of the impact on survival. \hyperref[b11]{[12]} And our last point: chemo maintenance? OPTIMOX trial showed no difference in survival compared to maintenance treatment until progression, so both options are a good idea and depends on the tolerabilty and performance status of each patient \hyperref[b12]{[13]} Learning Points/Take Home Messages ? Debut of rectal cancer with synchronous single and unique frontal brain metastasis is unusual. ? Overall survival in brain metastases from colorectal cancer is less than 6 months; achieving with \begin{quote} Figure Captions\end{quote} \begin{figure}[htbp] \noindent\textbf{}\includegraphics[]{image-2.png} \caption{\label{fig_0}}\end{figure} \begin{figure}[htbp] \noindent\textbf{123}\includegraphics[]{image-3.png} \caption{\label{fig_1}Figure 1 :Figure 2 :Figure 3 :}\end{figure} \begin{figure}[htbp] \noindent\textbf{} \par \begin{longtable}{P{0.8264200792602377\textwidth}P{0.023579920739762218\textwidth}} RT of primary tumor including pelvis and rectum\tabcellsep \\ in short course 5 sessions of 5Gy and subsequent LAR\tabcellsep \\ was accomplished on 25/11/13.\tabcellsep \\ Definitive Histological diagnosis: rectum\tabcellsep \\ adenocarcinoma ypT4b N2a (4/39) L0V1 R1 (radial\tabcellsep \\ margin) Wild KRAS type and mutated NRAS.\tabcellsep \\ Because of surgery infection, no possible\tabcellsep \\ "adjuvant" chemo. As brain margin affected and no\tabcellsep \\ chance of chemo, radiosurgery treatment in Central\tabcellsep \\ Nervous System (total dose of 35 Gy) was completed\tabcellsep \\ from 02/05/14 to 02/17/14.\tabcellsep \\ PET-CT reassessment at 2 months (figure 3):\tabcellsep \\ liver metastatic spread in both lobes (Sg II 6 mm, 19 mm Sg III, VIII 7 mm Sg, Sg V 20 mm) without other evidence of disease.\tabcellsep Year 2017\\ Not seen in previous CT, probably present.\tabcellsep \\ Performance Status 1. Chemotherapy treatment\tabcellsep \\ mFOLFOX6 +\tabcellsep \\ \tabcellsep D D D D ) F\\ \tabcellsep (\end{longtable} \par \caption{\label{tab_0}}\end{figure} \footnote{© 2017 Global Journals Inc. (US)} \backmatter \begin{bibitemlist}{1} \bibitem[Brown et al. ()]{b3}\label{b3} ‘Alliance): a phase III randomzed trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases’. P D Brown , A L Asher , K V Ballman . \textit{J Clin Oncol} 2015. 0574. (NCCTG. suppl; abstr LBA4) \bibitem[Magni et al. ()]{b2}\label{b2} ‘Brain metastases from colorectal cancer: main clinical factors conditioning outcome’. E Magni , P Santoro , Ravenda . \textit{Int J Colorectal Dis} 2014. 29 p. . \bibitem[Kye et al. (2012)]{b1}\label{b1} ‘Brain metastases from colorectal cancer: the role of surgical resection in selected patients’. B H Kye , H J Kim , W K Kang . \textit{Colorectal Dis} 2012 Jul. 14 (7) p. . \bibitem[Chu (2008)]{b11}\label{b11} ‘Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study’. E Chu . \textit{Clin Colorectal Cancer} 2008 Jul. 7 (4) p. 226. \bibitem[Schmoll et al. (2012)]{b10}\label{b10} ‘ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making’. H J Schmoll , E Van Cutsem , A Stein . \textit{Ann Oncol} 2012 Oct. 23 (10) p. . \bibitem[Pettersson et al. (2010)]{b8}\label{b8} ‘Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer’. D Pettersson , B Cedermark , T Holm . \textit{Br J Surg} 2010 Apr. 97 (4) p. . \bibitem[Tie et al. (2011)]{b6}\label{b6} ‘KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer’. J Tie , L Lipton , J Desai . \textit{Clin Cancer Res} 2011 Mar 1. 17 (5) p. . \bibitem[Morovic and Chang ()]{b4}\label{b4} ‘Literature review of various treatment plans and outcomes for’. J A Morovic , S D Chang . \textit{Brain Metastases from colorectal cancer World Neurosurg} 2011. 79 (3-4) p. . \bibitem[Sahgal et al. (2015)]{b5}\label{b5} ‘Phase 3 trials of stereotactic radiosurgery with or without wholebrain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis’. A Sahgal , H Aoyama , M Kocher . \textit{Int J Radiat Oncol Biol Phys} 2015 Mar 15. 91 (4) p. . \bibitem[Poultsides (2011)]{b12}\label{b12} ‘Reassessing the need for primary tumor surgery in unresectable metastatic colorectal cancer: overview and perspective’. G A Poultsides . \textit{Ther Adv Med Oncol} 2011 Jan. 3 (1) p. . \bibitem[Ko et al. (1999)]{b0}\label{b0} ‘Risk and patterns of brain metastases in colorectal cancer: 27-year experience’. F C Ko , J M Liu , W S Chen . \textit{Dis Colon Rectum} 1999 Nov. 42 (11) p. . \bibitem[Chau and Cunningham (2009)]{b13}\label{b13} ‘Treatment in advanced colorectal cancer: what, when and how?’. Chau , D Cunningham . \textit{Br J Cancer} 2009 Jun 2. 100 (11) p. . \bibitem[Adam et al. (2004)]{b9}\label{b9} \textit{Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg}, R Adam , G Pascal , D Castaing . 2004 Dec. 240 p. . \bibitem[Shin et al. (2011)]{b7}\label{b7} ‘Upfront systemic chemotherapy and preoperative short-course radiotherapy with delayed surgery for locally advanced rectal cancer with distant metastases’. S J Shin , Yoon Hii , N K Kim . \textit{Radiat Oncol} 2011 Aug 24. 6 p. 99. \end{bibitemlist} \end{document}